Prime-Target neoantigen vaccination unleashes unprecedented T cell immunity within “cold” immunosuppressive tumors
Authors:
- Kou HiokiKHKou Hioki
- Marlous WildemansMWMarlous Wildemans
- Youkyung LimYLYoukyung Lim
- Inge Brouwers–HaspelsIBInge Brouwers–Haspels
- Marjan van MeursMMMarjan van Meurs
- Eric BindelsEBEric Bindels
- Harmen J. G. van de WerkenHarmen J. G. van de Werken
- Yvonne M. MuellerYMYvonne M. Mueller
- Burcu TemizozBTBurcu Temizoz
- Ken J. IshiiKIKen J. Ishii
- Christopher SchlieheCSChristopher Schliehe
- Peter D. KatsikisPKPeter D. Katsikis
Preprint
Abstract
“Cold” immunosuppressive solid tumors are hard-to-treat cancers that are non-responsive to immunotherapies. Their immunosuppressive tumor microenvironment (TME) excludes and inhibits T cells and thereby hampers the therapeutic efficacy of cancer vaccines and immune checkpoint blockade. To overcome this, we employed a “Prime-Target” (P/T) neoantigen vaccination strategy that combines subcutaneous (SQ) and intra-tumor (IT) neopeptide vaccinations to first prime potent systemic neoantigen-specific T cell immunity and then trigger intratumoral T cell recruitment. Using immunotherapy non-responsive murine tumor models with pronounced immunosuppressive TMEs, we demonstrate that P/T neopeptide vaccination resulted in extraordinary tumor control and TME remodeling. P/T vaccination elicited strong systemic anti-tumor responses as well as potent and rapid recruitment of clonal CD4 + Th1 and non-exhausted CD8 + T cells into tumors that carried novel T cell receptors (TCR) and were vaccine neopeptide-specific. Concurrently, P/T vaccination reshaped the TME by decreasing suppressive Treg and M2 macrophages, and dramatically increasing the ratio of effector T cells to Treg and M2 macrophages. Vaccination-induced tumor control was neopeptide-dependent and required concurrent IT administration of both neopeptides and adjuvants. Our study highlights P/T neoantigen vaccination as a promising strategy to overcome T cell exclusion within “cold” immunosuppressive solid tumors and thereby unleash unprecedented anti-tumor immunity.Keywords
Funding Information
- Department of Immunology of Erasmus University Medical Center
- Dutch Cancer Society (KWF grant 12837)
- IMSUT International Joint Usage/Research Center Project (K22-3063)
- IMSUT International Joint Usage/Research Center Project (K25-3190)
This publication has 55 references indexed in Scilit:
- Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsCancer Cell, 2024
- Targeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunityClinical and Translational Oncology, 2023
- scDemultiplex: An iterative beta-binomial model-based method for accurate demultiplexing with hashtag oligosComputational and Structural Biotechnology Journal, 2023
- Cancer cell-derived type I interferons instruct tumor monocyte polarizationCell Reports, 2022
- A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cellsCell, 2021
- Top 10 Challenges in Cancer ImmunotherapyImmunity, 2020
- High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer TherapyCell, 2018
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines2016
- The interplay of effector and regulatory T cells in cancerCurrent Opinion in Immunology, 2015